
Gilead’s Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1-Positive Metastatic Triple-...
Topline findings from Gilead’s Phase III ASCENT-04/KEYNOTE-D19 study found that the combination of Trodelvy (sacituzumab govitecan-hziy) and Keytruda (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda plus …